NIH-funded research R01 grant

Understanding how certain proteins affect vision development

Official title: Dissecting the role of aggrecan and perineuronal nets in visual plasticity

Funded at University of Louisville · NIH-10913638 · Data updated 2026-11-12

This study is looking at how certain proteins in the brain help our vision develop and adapt during important growth stages, which could lead to better treatments for conditions like lazy eye.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Louisville
NIH-funded
Lab location1 site (Louisville, United States)
Project startSeptember 1, 2023
Project endJune 30, 2027
Funding year2024
Award (this year)$461,687
NIH project number5R01EY035138-02
Project IDNIH-10913638 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for participation or benefit include children and young adults with amblyopia or related visual disorders.

Less likely to help

Patients with visual disorders unrelated to critical period plasticity may not receive benefit from this research.

What this research studies

This research investigates the role of aggrecan and perineuronal nets in the visual system's ability to adapt and change during critical developmental periods. By studying animal models, the research aims to uncover how these proteins influence the closure of critical periods for visual plasticity, which is essential for treating conditions like amblyopia. The approach includes behavioral tests, electrophysiological recordings, and genetic techniques to explore the mechanisms behind visual circuit development and plasticity. Patients may benefit from insights that could lead to improved therapies for visual disorders.

Why it matters

Potential benefit: If successful, this research could lead to new treatment strategies for visual disorders like amblyopia, particularly in children.

How similar studies have gone: Previous research has shown promising results in understanding visual plasticity, but this specific approach focusing on aggrecan is relatively novel.

Where this research is happening

  • University of Louisville
    Louisville, United States
    Active

Researchers

  • Principal investigator: Mcgee, Aaron W — University of Louisville
  • Study coordinator: Mcgee, Aaron W

Related research

Other NIH-funded projects on the same topics.

  • Gastric rhythm map to understand stomach problems using a new noninvasive tool

    A new noninvasive body surface mapping method is being tested to see if abnormal stomach electrical rhythms explain chronic stomach problems like functional dyspepsia and persistent nausea.

    NIH research University of Louisville · Louisville, United States · NIH-11611507

  • Novel antivirals for alphavirus arthritis

    A research team is refining a promising antiviral compound to treat alphavirus infections that cause arthritis, with a focus on Chikungunya and related viruses.

    NIH research University of Louisville · Louisville, United States · NIH-11609180

  • Linking heavy metal exposure to a tougher breast cancer type (TNBC)

    Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

    NIH research University of Louisville · Louisville, United States · NIH-11567535

  • Cardiac safety of flavored e-cigarette aerosols in adults

    A pharmacist or clinician would test how inhaling flavored e-cigarette aerosols affects heart rhythm in adults to see if flavors raise the risk of heart problems.

    NIH research University of Louisville · Louisville, United States · NIH-11541950

  • Biomedical Research Facilities to Expand Precision Medicine in Kentucky

    A large NIH grant aims to renovate and expand a shared precision medicine center in Kentucky to speed up research that could improve health for people in Appalachia and surrounding areas.

    NIH research University of Louisville · Louisville, United States · NIH-11523167

  • Rac-enhanced CAR-Macrophages against TNBC

    A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

    NIH research University of Louisville · Louisville, United States · NIH-11520503

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.